Research programme: red blood cell therapeutics - Rubius Therapeutics

Drug Profile

Research programme: red blood cell therapeutics - Rubius Therapeutics

Alternative Names: RCT-Rubius; Red-Cell Therapeutic

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rubius Therapeutics
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Enzyme replacements; Immunomodulators; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Phenylketonuria
  • Research Autoimmune disorders; Cancer

Most Recent Events

  • 27 Sep 2017 Rubius Therapeutics intends to initiate clinical development in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top